KAZIMI A J

A. J. Kazimi, Chairman and CEO of Cumberland Pharmaceuticals (CPIX), has filed 150 Form 4 transactions that collectively show a pronounced buy-and-hold posture with zero open-market sales. The aggregate data reveals approximately $2,835 in total purchase value against no sell value, while the bulk of his activity consists of compensation-related awards and automatic tax withholdings. The most significant recent event was a March 18, 2026 grant (code "A") valued at $280,000, followed two days later by a tax-withholding transaction (code "F") of $17,885.70 — a pattern typical of an executive receiving equity compensation and immediately surrendering shares to cover tax obligations. The remainder of Kazimi's recent filings are dominated by small "L" transactions — minor adjustments or corrections — ranging from $27.37 to $45.78 per trade, filed nearly daily from late November through December 2025. These negligible dollar amounts suggest administrative updates rather than discretionary trading decisions. Notably, there are no open-market purchases (code "P") or sales (code "S") in the recent window, meaning Kazimi has not used his own capital to acquire CPIX shares on the open market during this period, nor has he liquidated any holdings. The overall picture is one of a long-tenured insider whose Form 4 activity is driven by scheduled compensation events and routine administrative filings rather than active conviction trading. The absence of any sell transactions — whether open-market sales or issuer buybacks — indicates Kazimi has maintained his position without trimming, while the $280,000 grant in March 2026 represents the only material value change in recent months. For investors monitoring insider behavior, the data shows no signal of either accumulation or distribution beyond what compensation mechanics would dictate.